scholarly article | Q13442814 |
P356 | DOI | 10.1016/J.VACCINE.2017.10.098 |
P698 | PubMed publication ID | 29153584 |
P50 | author | Ab Osterhaus | Q354237 |
Jan Franciszek Żmudziński | Q11717471 | ||
Michał Reichert | Q11779161 | ||
Anna Marzec | Q88344884 | ||
Marcin Smreczak | Q89976803 | ||
Anna Kycko | Q94556389 | ||
Paweł Trębas | Q125344472 | ||
P2093 | author name string | Anna Orłowska | |
Penelopa Koraka | |||
P2860 | cites work | Ambivalent role of the innate immune response in rabies virus pathogenesis | Q24300579 |
Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases | Q24632768 | ||
TNF inhibitor therapy for rheumatoid arthritis | Q28972424 | ||
Rabies virus-induced activation of mitogen-activated protein kinase and NF-kappaB signaling pathways regulates expression of CXC and CC chemokine ligands in microglia | Q33987385 | ||
Met-CCL5 represents an immunotherapy strategy to ameliorate rabies virus infection. | Q34571301 | ||
Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases | Q35221333 | ||
Profile of Cytokines and Chemokines Triggered by Wild-Type Strains of Rabies Virus in Mice | Q36575430 | ||
GRP78/Dna K Is a Target for Nexavar/Stivarga/Votrient in the Treatment of Human Malignancies, Viral Infections and Bacterial Diseases | Q36830763 | ||
The importance of immune evasion in the pathogenesis of rabies virus. | Q37157195 | ||
Raf inhibitors as therapeutic agents against neurodegenerative diseases | Q37702342 | ||
Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases. | Q37854935 | ||
Tocilizumab: a novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic diseases | Q38104740 | ||
TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants - past, present and future | Q38244471 | ||
Modern anti-cytokine therapy of autoimmune diseases | Q38365336 | ||
The type I interferon response bridles rabies virus infection and reduces pathogenicity | Q39497376 | ||
Interleukin-6 inhibitors in the treatment of rheumatoid arthritis. | Q40003399 | ||
Exogenous interferon prolongs survival of rabies infected mice. | Q40986580 | ||
Pathobiology of rabies virus and the European bat lyssaviruses in experimentally infected mice. | Q42280815 | ||
Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor | Q44054852 | ||
Silver-haired bat rabies virus variant does not induce apoptosis in the brain of experimentally infected mice | Q45734834 | ||
Up-regulation of chemokine gene transcripts and T-cell infiltration into the central nervous system and dorsal root ganglia are characteristics of experimental European bat lyssavirus type 2 infection of mice | Q56773297 | ||
Glycoprotein-mediated induction of apoptosis limits the spread of attenuated rabies viruses in the central nervous system of mice | Q60696936 | ||
P433 | issue | 33 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | rabies | Q39222 |
rabies virus | Q698976 | ||
murine model | Q122890741 | ||
P304 | page(s) | 4715-4723 | |
P577 | publication date | 2017-11-15 | |
P1433 | published in | Vaccine | Q7907941 |
P1476 | title | The effect of selected molecules influencing the detrimental host immune response on a course of rabies virus infection in a murine model | |
P478 | volume | 37 |
Q56576670 | Combination drug treatment prolongs survival of experimentally infected mice with silver-haired bat rabies virus |
Q59353657 | Inhibition of MALT1 decreases neuroinflammation and pathogenicity of virulent rabies virus in mice |
Q54236746 | The effect of combined drugs therapy on the course of clinical rabies infection in a murine model. |
Search more.